News

BlogsPosts
As Seen In
Canadian Technology and Innovation: making strides in the global cell therapy landscape
Another cell therapy rising star, RepliCel Life Sciences, is harnessing the
BlogsPosts
As Seen In
Company Uses Patients' Own Cells to Put an End to Baldness, Aging Skin and Tendon Degeneration
Company Uses Patients' Own Cells To Put An End To Baldness, Aging Skin And Tendon
BlogsPosts
As Seen In
Regenerative medicine: Interview with a game-changing leader
Regenerative medicine is a game-changing area of medicine. It has the potential to fully heal
BlogsPosts
As Seen In
Poised for Success with Positive Clinical Results
To read the full interview as it appears on Costmeticosbr.com.br, click here (7/6/17).
BlogsPosts
As Seen In
Your Hair Could Hold The Secret To Mending Your Injured Tendon
To read the full article as it appears on Pridenews.ca , click here
BlogsPosts
As Seen In
Exclusive Interview with RepliCel Life Sciences President and CEO Lee Buckler
To read the full article as it appears on SmarterAnalyst.com by Julie Lamb, click here.
BlogsPosts
As Seen In
RepliCel, cell therapy companies ready to give you athletic immortality
To read the full article as it appears on Metro News by Matt Burke, click
BlogsPosts
As Seen In
RepliCel Developing Autologous Cell Therapies For Skin, Hair and Tendon Regeneration
To read the full interview as it appears on MedicalResearch.com, click here. (4/22/17)
BlogsPosts
As Seen In
RepliCel – Stem Cell Therapies Using Your Own Cells
To listen to Podcast and View Transcript on Future Tech Podcast, click here
BlogsPosts
As Seen In
Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis (ReaCT)
To read the full study as it appears on ClinicalTrials.gov, click here.
BlogsPosts
Press Release
RepliCel’s Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems
First-in-human clinical study meets primary endpoint demonstrating product safety and clinical potential for tendon regeneration
BlogsPosts
As Seen In
ESPN with Bill Daughtry
Listen: http://www.espn.com/espnradio/newyork/play?id=18570324 (at the 1:38 mark)
BlogsPosts
As Seen In
Will 2017 be the year of Cell Therapies?
To read the full article as it appears on The Huffington Post, click here. (1/20/17) While
BlogsPosts
As Seen In
RepliCel – Using Cells for Healing
View featured company Article on Advisor Access click here
BlogsPosts
As Seen In
RepliCel CEO Lee Buckler talks to Cantech Letter
View Article by Nick Waddell on Cantech Letter click here
BlogsPosts
Press Release
RepliCel Life Sciences conducts formal consultation review with Japan’s PMDA and receives unprecedented review fee reduction
Japan’s Pharmaceuticals and Medical Devices Agency reviews RepliCel’s pre-clinical, quality, and manufacturing data for its
BlogsPosts
Press Release
RepliCel Life Sciences Finishes Enrolment for its Tendon Repair and Skin Rejuvenation Clinical Trials
Results from both trials will support commercialization initiatives, partner discussions and continued clinical development VANCOUVER, BC
BlogsPosts
As Seen In
Canada’s emerging cell therapy biotech industry
Canadian companies driving global breakthroughs in regenerative medicine By Kathryn Boothby To read this article
BlogsPosts
As Seen In
5 Questions with David Hall
Click here to view the article on Cantech Letter Vancouver-based RepliCel Life Sciences (TSXV:RP)
BlogsPosts
Press Release
RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis
ReaCT Trial at University of British Columbia Treating Patients with Autologous CellTherapy VANCOUVER, BC – June

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.